HTGF co-leads €3m seed round for Atriva

Dutch investor Stichting Participatie Atriva co-led with HTGF and Canadian biotechnology VC investor InSynchrony Ventures also taking part.

The seed round closed its first tranche in February 2017 with backing from HTGF. The second tranche of the seed funding has now also closed making the total value of both tranches €3m.

Atriva simultaneously announced the identification of an optimised formulation approach for ATR-002, an important pre-clinical milestone on the path to clinical development.

The company says that this financing will enable it to enter clinical development by the first half of 2018 and proof of concept by late 2019.

Company
Atriva was founded in 2015 and is located in Tübingen, Germany. Three viral research scientists and five industry experts started the company and established or transferred five broad patent families relating to antiviral use. These patents protect the core technology until 2035.

The drugs the company is developing would block the replication of viruses such as influenza so that it could be controlled in high-risk patients. The company estimates the addressable global market potential of such an inhibitor to exceed €2.8bn.

People
High-Tech Gründerfonds – Frank Hensel (senior investment manager).
Atriva Therapeutics – Rainer Lichtenberger (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• High-Tech Gründerfonds
• seed
• Germany